Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
| Descrizione | Lingua | Dimensioni | Downloads | |
|---|---|---|---|---|
 |
IT | 965 kB | 904 |
IARC Monographs on the Identification of Carcinogenic Hazards to Humans Volume 128: Acrolein, Crotonaldehyde and Arecoline
This volume of the IARC Monographs provides evaluati...
Regolamento delegato (UE) 2015/2229 della Commissione del 29 settembre 2015 recante modifica dell'allegato I del regolamento (UE) n. 649/2012 del Parlamento europeo ...
Ratifica ed esecuzione della convenzione sulla protezione fisica dei materiali nucleari, con allegati, aperta alla firma a Vienna ed a New York il 3 marzo 1980.
(GU n.277 del ...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024